Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments

OBJECTIVE: Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). DESIGN: by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples. RESULTS: in the plasma that was subclonal in the tumour for one patient and not detectable in the tumour for the other one. CONCLUSION: ctDNA offers dynamic information reflecting tumour biology. It represents a non-invasive tool useful to guide HCC clinical management.